Prevention of Chemotherapy-Induced Neutropenia with Pegfilgrastim: Pharmacokinetics and Patient Outcomes

Pharmacokinetics and Pharmacodynamics of Pegfilgrastim

(2011) Bing-Bing Yang et al.   CLINICAL PHARMACOKINETICS

PEGylation of therapeutic proteins

(2010) Simona Jevševar et al.   Biotechnology Journal

A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy

(2010) J. Randolph Hecht et al.   Clinical Colorectal Cancer

Phase II, Randomized, Open-Label Study of Pegfilgrastim-Supported VDC/IE Chemotherapy in Pediatric Sarcoma Patients

(2010) Sheri L. Spunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute Myeloid Leukemia or Myelodysplastic Syndrome in Randomized Controlled Clinical Trials of Cancer Chemotherapy With Granulocyte Colony-Stimulating Factor: A Systematic Review

(2010) Gary H. Lyman et al.   JOURNAL OF CLINICAL ONCOLOGY

Population Modeling of Filgrastim PK-PD in Healthy Adults Following Intravenous and Subcutaneous Administrations

(2010) Wojciech Krzyzanski et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non–Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies

(2010) Howard A. Burris et al.   Journal of Oncology Practice

Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG

(2009) J. Braess et al.   BLOOD

A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer

(2009) R L Jones et al.   BRITISH JOURNAL OF CANCER

Chemotherapy-induced anemia in breast cancer patients treated with pegfilgrastim-supported dose-dense regimens

(2009) Mariangela Manzoni et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Population Pharmacokinetic Modelling of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations

(2009) Pawel Wiczling et al.   CLINICAL PHARMACOKINETICS

Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study

(2009) Derek Weycker et al.   CLINICAL THERAPEUTICS

Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy

(2009) Matti Aapro et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

(2009) Ulrich Gatzemeier et al.   Journal of Thoracic Oncology

Pegfilgrastim Administered on the Same Day with Dose-Dense Adjuvant Chemotherapy for Breast Cancer Is Associated with a Higher Incidence of Febrile Neutropenia as Compared to Conventional Growth Factor Support: Matched Case-Control Study of the Hellenic Cooperative Oncology Group

(2009) Dimosthenis V. Skarlos et al.   ONCOLOGY

The Impact of PEGylation on Biological Therapies

(2008) Francesco M Veronese et al.   BIODRUGS

A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

(2008) Jorge Sierra et al.   BMC CANCER

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis

(2008) G. von Minckwitz et al.   EUROPEAN JOURNAL OF CANCER

Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor–expanding uses in cancer chemotherapy

(2008) Mariko Morishita et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Pharmacokinetics and Pharmacodynamics of Pegfilgrastim in Subjects With Various Degrees of Renal Function

(2008) Bing-Bing Yang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Phase II Randomized Study of Dose-Dense Docetaxel and Cisplatin Every 2 Weeks With Pegfilgrastim and Darbepoetin Alfa With and Without the Chemoprotector BNP7787 in Patients With Advanced Non-small Cell Lung Cancer (CALGB 30303)

(2008) Antonius A. Miller et al.   Journal of Thoracic Oncology

Biological Effects of Pegfilgrastim on Circulating Neutrophils in Breast Cancer Patients Undergoing Dose-Dense Chemotherapy

(2008) Rosangela Invernizzi et al.   ONCOLOGY

Pegfilgrastim   ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study

(2007) G. von Minckwitz et al.   ANNALS OF ONCOLOGY

Economic Analysis of Prophylactic Pegfilgrastim in Adult Cancer Patients Receiving Chemotherapy

(2007) Adi Eldar-Lissai et al.   VALUE IN HEALTH